Charles River Laboratories Intl. Inc vs Uranium Energy Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.1× Uranium Energy Corp's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Uranium Energy Corp for 37 Days on average.
| CRL | UEC | |
|---|---|---|
Market Cap | $14.23B | $4.53B |
Volume | 1,176,885 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $310.77 | $20.14 |
52-Week Low | $149.93 | $9.04 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $17.06B | $4.03B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Uranium Energy (UEC) trades at $9.19, down 2.96% in the last session. The stock shows bearish technical signals with negative earnings momentum, posting losses in recent quarters despite revenue growth. The company is expanding its US uranium mining operations with two active mines, benefiting from increased government demand for domestic nuclear fuel. Analyst sentiment remains overwhelmingly positive with 87.5% buy ratings and a $16.06 consensus price target, though fundamental metrics show significant losses with a -368.62% net income margin.
UEC presents a high-risk, high-reward opportunity with strong Wall Street support but concerning financials. The bullish case hinges on nuclear energy expansion and domestic uranium demand growth, while risks include sustained operational losses, unproven production sustainability, and heavy reliance on financing activities. Current valuation appears stretched given negative profitability metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →